2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

卷:72

Article

Das, Sandeep R.¹  Everett, Brendan M.²  Birtcher, Kim K.³  Brown, Jenifer M.⁴  Cefalu, William T.⁵  Januzzi, James L., Jr.⁶  Kalyani, Rita Rastogi⁷  Kosiborod, Mikhail^8,9  Magwire, Melissa L.¹⁰  Morris, Pamela B.^11,12  Sperling, Laurence S.^13,14 

[1] UT Southwestern Med Ctr, Med, Dallas, TX 75390 USA

[2] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

[3] Univ Houston, Coll Pharm, Houston, TX 77030 USA

[4] Brigham & Womens Hosp, Cardiol, 75 Francis St, Boston, MA 02115 USA

[5] Amer Diabet Assoc, Arlington, VA USA

[6] Harvard Med Sch, Massachusetts Gen Hosp, Med, Boston, MA USA

[7] Johns Hopkins Univ, Sch Med, Med, Baltimore, MD USA

[8] St Lukes Mid Amer Heart Inst, Kansas City, MO USA

[9] Univ Missouri, Med, Kansas City, MO 64110 USA

[10] Shawnee Mission Hlth Endocrine Clin, Merriam, KS USA

[11] Med Univ S Carolina, Cardiovasc Hlth Program, Charleston, SC 29425 USA

[12] Womens Heart Care, New York, NY USA

[13] Emory Heart Dis Prevent Ctr, Med Cardiol, Atlanta, GA USA

[14] Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Global Hlth, Atlanta, GA 30322 USA

关键词: ASCVD;    cardiovascular risk reduction;    diabetes;    Expert Consensus Decision Pathway;    GLP-1RA;    SGLT2 inhibitor;    T2D;   

DOI  :  10.1016/j.jacc.2018.09.020

来源: Elsevier

【 授权许可】

Free